BioWorld

May 2, 2006

CardioKine Brings In $50M Via Series B For Lixivaptan

CardioKine Inc., just 2 years old, is ready to move its lead product, Lixivaptan, into Phase III trials, and it raised $50 million to do so. (BioWorld Today) Read More

NeoPharm Trimming Jobs To Contain Costs Going Forward

GAO Recommends Improved Post-Approval Drug Oversight

Vaccinoma Files Australian IPO For Melanoma Vaccine

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 29, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...